Results 271 to 280 of about 3,498,043 (366)

Advancements in tissue engineering for cardiovascular health: a biomedical engineering perspective. [PDF]

open access: yesFront Bioeng Biotechnol
Razavi ZS   +8 more
europepmc   +1 more source

Evolving Platinum‐Copper Nanostructures for Enhanced Photothermal Therapy and Controlled Copper Release in Cancer Therapy

open access: yesAdvanced Functional Materials, EarlyView.
Platinum‐Copper bimetallic nanoparticles may evolve depending on their synthesis under tumor microenvironment conditions and play a dual role as chemotherapeutic agents after releasing Cu ions and as near infrared photothermal agents with the Pt‐rich remaining frames.
Jose I. Garcia‐Peiro   +7 more
wiley   +1 more source

Adalimumab‐Poloxamer Conjugate for Bio‐Better: Enhanced Stability and Function

open access: yesAdvanced Functional Materials, EarlyView.
Antibody‐polymer conjugates, particularly poloxamer conjugates, enhance antibody stability by improving tolerance to physicochemical stress and attenuating proteolysis by proteases. Furthermore, the higher affinity observed with poloxamer conjugation compared to standard PEGylation results in improved therapeutic efficacy in rheumatoid arthritis mouse ...
Jaewon Roh   +3 more
wiley   +1 more source

Endocytic Programming via Porous Silicon Nanoparticles Enhances TLR4 Nanoagonist Potency for Macrophage‐Mediated Immunotherapy

open access: yesAdvanced Functional Materials, EarlyView.
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang   +9 more
wiley   +1 more source

Cholesterol in mRNA‐Lipid Nanoparticles can be Replaced with the Synthetic Mycobacterial Monomycoloyl Glycerol Analogue MMG‐1

open access: yesAdvanced Functional Materials, EarlyView.
This study demonstrates that cholesterol in messenger RNA‐lipid nanoparticles (mRNA‐LNPs) can be completely replaced with an immunopotentiating lipid, i.e., a synthetic analogue of the C‐type lectin receptor agonist monomycoloyl glycerol (MMG‐1), without compromising physicochemical properties, in vivo transfection efficiency, and immunogenicity of the
Abhijeet G. Lokras   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy